Latham Advises Peptone on US$40 Million Series A Financing Round

Funds raised will be used to establish world leading facility for protein drug discovery.

June 13, 2022

Latham & Watkins has advised Peptone, a molecular computational physics company focused on protein drug discovery, on its US$40 million Series A financing round. Peptone’s technology combines computational molecular physics and neural networks to analyse the behaviour and structure of proteins. It is used in a variety of pre-clinical and late-stage protein therapeutics programs. The fundraising will be used to develop the world’s most advanced facility dedicated to solving complex and problematic intrinsically disordered protein structures at scale, pioneering a new class of potential therapeutic targets and drugs.

The round was led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures and existing investors, including Hoxton Ventures and dRX Capital, the venture arm of Novartis.

The Latham team was led by London corporate partner Shing Lo, with associate Aaron Bassett.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.